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ABSTRACT
neXtProt (http://www.nextprot.org) is a human
protein-centric knowledgebase developed at the SIB
Swiss Institute of Bioinformatics. Focused solely on
human proteins, neXtProt aims to provide a state
of the art resource for the representation of human
biology by capturing a wide range of data, precise
annotations, fully traceable data provenance and a
web interface which enables researchers to find and
view information in a comprehensive manner. Since
the introductory neXtProt publication, significant ad-
vances have been made on three main aspects: the
representation of proteomics data, an extended rep-
resentation of human variants and the development
of an advanced search capability built around seman-
tic technologies. These changes are presented in the
current neXtProt update.
INTRODUCTION
neXtProt (http://www.nextprot.org) is a web-based knowl-
edge platform focusing on human proteins. Similarly to
Model Organism Databases (MODs) which serve to col-
late data and provide an impetus for research on model
species, the goal of neXtProt is to serve as a one-stop shop
for research on human proteins by providing a representa-
tion of the current state of knowledge in a manner that is
at once both comprehensive and of high quality. Since the
first publication on neXtProt (1), we have continued to ex-
pand the database. We have developed close collaborations
with two major user groups: proteomics researchers, who
use mass spectrometry techniques to identify the different
protein forms present in biological samples and biomedi-
cal researchers working on elucidating how genetic varia-
tions in protein-coding sequences can lead to disease. Our
recent work has been mostly focused on integrating data
from these two areas of human biology, with extensive qual-
ity control procedures. Major efforts have been undertaken
on the search and retrieval capacities of neXtProt in order to
take into account the richness of annotations and evidences
so as to support the retrieval of proteins based on highly
precise criteria as well as to allow programmatic data access.
The next sections of this paper describe these improvements
in detail.
NEW neXtProt CONTENT
neXtProt continuously adds new content to the database.
Table 1 displays the information contained in neXtProt
as of October 2014. The major data sources include Bgee
(2), HPA (3), Peptide Atlas (4), SRMAtlas (5), UniPro-
tKB (6), GOA (7), dnSNP (8), Ensembl (9), COSMIC (10),
DKFGFP--cDNA localization (11,12),Weizmann Institute
of Science’s KahnDynamic Proteomics Database (13), and-
IntAct (14).
In addition to the data presented in Table 1, neXtProt
provides (i) mappings of proteins to their Ensembl genomic
transcripts on the human genome; (ii) associations with
over 800 000 identifiers, including cDNA clone names en-
coding for the proteins, Affymetrix and Illumina DNA
probe sets; (iii) cross-references to CCDS (15), HPRD (16);
and (iv) abstracts of all articles from PubMed that are
cited in human UniProtKB/Swiss-Prot entries as well as
some cited by other resources such as Entrez Gene (GeneR-
IFs) (17), MINT (18), and PDB (19) and which have been
computationally mapped to the relevant protein entry by
the UniProt consortium, totaling over 400 000 references.
We have also recently integrated a 3D structure visual-
ization applet––BioViz––developed by BIONEXT (http://
www.bionext.com). The current version of the applet allows
users to zoom, select regions or position-specific annota-
tions (such as post-translationalmodifications (PTMs)) and
view them in the context of the 3D structure, in addition to
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Table 1. neXtProt contents in the October 2014 release
Data type Number of annotationsa Source
Anatomical (cell types/tissues/organs)
expression
1 823 655 Gold/1 263 848 Silver Bgee (microarray and ESTs) (2) and HPA
(immunohistochemistry) (3)
Mass spectrometry-identified peptides 1 090 163, all Gold PeptideAtlas (4), SRMAtlasb (5), and direct
integration of results of research articles
Post-translational modifications 94 019 Gold/8575 Silver UniProtKB (6) and direct integration of results of
research articles
Gene Ontology annotations 136 852 Gold/54 712 Silver GOA (7)
Variants 70 262 Gold/1 081 000 Silver UniProtKB, dbSNP (8) (via Ensembl (9)),
COSMIC (10)
Subcellular localizations 26 148 Gold/8582 Silver UniProtKB, HPA, GOA, DKF GFP-cDNA
localization (11,12); and Weizmann Institute of
Science’s Kahn Dynamic Proteomics Database (13)
Interactions 9467 Gold/71 911 Silver UniProtKB and Intact (14)
aGold and Silver quality assignment varies by data source and has been set in accordance with data providers whenever possible (1); see also (21) for quality
assignment regarding HPA.
bNew in the October 2014 release.
highlighting them in the graphic, table and sequence views
of the Structures page for an entry.
FOCUS ON PROTEOMICS
HUPO, the Human Proteome Organization (http://www.
hupo.org), is an international group that connects all lab-
oratories using proteomics as an approach to characterize
human proteins in healthy and disease samples. HUPO’s
Human Proteome Project (HPP; http://www.thehpp.org
(20)) aims to make a comprehensive inventory of all pro-
teins with respect to their existence, the different iso-
forms expressed, post-translational modifications as well
as their abundance, distribution and subcellular localiza-
tion. neXtProt has been selected as the knowledge resource
for the HPP project (21). As such, neXtProt’s role within
the HPP project is to integrate the results of the mass-
spectrometry (MS) identification studies that are flagged as
being part of HPP; provide metrics concerning the progress
of the project (which proteins still need to be identified by
proteomics); and represent the extent of our knowledge of
human proteins’ properties and functions in the best possi-
ble manner.
PeptideAtlas (5), developed at the Seattle Proteome
Center, is a close collaborator on the HPP project (4).
PeptideAtlas collects raw results from proteomics experi-
ments and reinterprets themusing a uniform computational
pipeline, the Trans-Proteomic Pipeline (22), with a stringent
false-discovery rate cut off of 1%. PeptideAtlas provides
peptide identification in biological samples, i.e. protein ex-
istence validation. PeptideAtlas has proteomics data from
multiple tissues and fluids: plasma, urine, brain, kidney,
heart, liver, lung, digestive system, pancreas, spleen, eye,
breast, adrenal gland, urinary bladder and female and male
reproductive systems. On its proteomics page, neXtProt
presents peptides identified in experiments integrated by
PeptideAtlas. Moreover, neXtProt displays the tissues in
which a peptide was identified in the Evidences column
of the table view. Another project of the Seattle Proteome
Center is the SRMAtlas, an atlas of peptides detected by
Selected Reaction Monitoring (23). This technique is cur-
rently the most precise method for quantifying peptides by
mass spectrometry. SRMAtlas provides tools (i.e. synthetic
peptides spectra) to allow protein identification and quanti-
tation in biological samples. As of October 2014, neXtProt
displays the peptides validated by SRMAtlas (Figure 1).
neXtProt also integrates data directly from high-
throughput studies. We have integrated 21 papers with
post-translational modifications, covering several dif-
ferent types of modifications: phosphorylation, N- and
O-glycosylation, sumoylation, ubiquitylation, acetylation
and methylation. Again, only high quality data is loaded,
based on stringent criteria that vary from paper to paper,
but that usually require a protein false discovery rate
(FDR) of 1% of less.
neXtProt EXTENDS THE COVERAGE OF IDENTIFIED
PROTEINS IN THE HUMAN PROTEOME
As described previously (21), neXtProt uses data from
UniProtKB and from proteomics studies to assign levels
of evidence for protein existence applying the same criteria
as UniProtKB: (i) evidence at protein level (e.g. identifica-
tion by mass spectrometry, or detected by antibodies, or se-
quenced by Edman degradation, or that its tridimensional
structure has been resolved, (ii) evidence at transcript level
(e.g. ESTs or full length mRNA), (iii) inferred by homol-
ogy (strong sequence similarity to known proteins in related
species), (iv) predicted (gene models) and (v) uncertain (e.g.
dubious sequences that are likely the products of erroneous
translations of pseudogenes). The October 2014 release of
neXtProt contains 16 491 entries validated at the protein
level out of 20 055 entries, or 82%, compared with 15 603 in
the October 2013 release, a 4% increase. TheUniProtKB re-
lease 2014 08 contains 13 988 human entries validated at the
protein level. Thus, the integration of additional proteomics
data has meant that neXtProt has integrated experimental
evidence for the existence of 2503 additional entries.
FOCUS ON VARIANTS
Across the whole spectrum of human population, there are
millions of variations in protein sequences (24), most of
which having no consequence on health. However a great
challenge that derives from easier access to exome and
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Figure 1. The neXtProt proteomics view displays a new track for ‘SRM Peptides’ that have been chemically synthesized and validated by SRMAtlas.
As for the other views displaying sequences, the graphical view, the table and the sequence are linked together, so that upon selection of a peptide in the
graphical view, it is highlighted in the table and in the sequence. As shown by the peptide selected above, some SRMpeptides correspond to natural peptides
identified in biological samples; in this case they are shown twice, with their respective evidences.
whole genome sequencing is trying to identify those muta-
tions that may cause a pathologic effect or increase the risk
to certain diseases. With our expertise on human protein
function, we have embarked on a project of annotation of
protein variants implicated in hereditary cancers. To do so,
we are developing an annotation platform to annotate pro-
tein function and mutant phenotypes, which is still at the
prototypical stage and will be presented in a future publica-
tion. In order to annotate protein variants as exhaustively as
possible, we have integrated mutations from the COSMIC
database (10), and are in the process of integrating those
fromClinVar (25). The variants we are integrating are those
that affect protein sequence, and are of type: substitution,
insertion and deletion.
Disease and cell line mappings
neXtProt strives to support interoperability with other
resources by using standard vocabularies and ontologies
whenever possible. When this is not possible, we construct
vocabularies and mappings that we make publicly available
on our FTP site. COSMIC uses its own internal classifica-
tion system to describe diseases and cell lines. This led us
to develop two resources, the Cosmosaurus and the Cel-
losaurus, to address this issue.
The Cosmosaurus: a mapping between COSMIC and the
NCI Thesaurus
We have created a mapping between COSMIC and the NCI
Thesaurus (26). This mapping is named ‘Cosmosaurus’. In
COSMIC, each sample is described using four fields: ‘Pri-
mary site’, ‘Site subtype’, ‘Primary histology’ and ‘Histol-
ogy subtype’. The Cosmosaurus treats each distinct com-
bination of these four fields as a synonym (SY) for a NCI
entry, defined by its NCI Thesaurus term (ID) and acces-
sion (AC). The mapping was developed in-house, with the
invaluable help of COSMIC biocurators. An example of a
Cosmosaurus mapping is shown below. In this case, four
different combinations of COSMIC sample descriptions are
mapped onto a single NCI term. The version of July 2014
contains 1706 COSMIC terms mapped to 736 NCI The-
saurus terms.
ID Colorectal Tubular Adenoma
AC C27456
SY large intestine, caecum, adenoma, tubular
SY large intestine, left, adenoma, tubular
SY large intestine, NS, adenoma, tubular
SY large intestine, right, adenoma, tubular
The Cellosaurus: an extensive glossary of cell lines
Many of the data annotated in COSMIC come from cell
lines. Unfortunately, there was no comprehensive standard-
ized resource describing cell lines. To address this, we have
developed a new controlled vocabulary, the Cellosaurus,
which, as far as we know, is the most comprehensive re-
source on cell lines (Bairoch, in preparation). The Cel-
losaurus is constantly growing; the version of September
2014 contains over 32 000 cell lines from 240 species (74%
from human, 14% from mouse), 21 000 synonyms and 23
000 publication references to over 6500 publications. COS-
MIC samples originating from a cell line are mapped to a
Cellosaurus unique identifier.
FOCUS ON SEARCH AND DATA RETRIEVAL
We have completely restructured the neXtProt data model
and infrastructure. The objective of these changes was to
allow neXtProt users to precisely extract information that
they are interested in; to manage list of proteins (originat-
ing from the results of searches, or created by users); and
build analysis tools on top of neXtProt. Figure 2 gives an
overview of the new neXtProt architecture and the tech-
nologies used.
With the new architecture, all the data in neXtProt is now
accessible via a REST API. The REST API decouples the
database from all our services; in particular, the search and
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Figure 2. The new neXtProt infrastructure. neXtProt implements the
following software and packages: Spring: open source web applica-
tion over Java (spring.io); Spring JDBC templates: thin API between
database and data objects (http://docs.spring.io/spring/docs/3.0.x/spring-
framework-reference/html/jdbc.html); PostgreSQL: database where se-
quences, annotations, evidences and terms, as well as user resources
(profiles, saved lists and queries) are stored (http://www.postgresql.org);
Lucene/solr: full-text search engine for simple search queries (http://lucene.
apache.org and http://lucene.apache.org/solr); Jena: graph search API for
complex search queries (http://jena.apache.org); and Virtuoso: to store
RDF data and perform complex SPARQL search queries (http://virtuoso.
openlinksw.com).
the export services. Importantly for our users, the REST
API provides an easy access to all data such that third par-
ties can build applications on top of neXtProt.
Results from neXtProt searches are linked to a protein
list management tool (Figure 3). Users can create new lists,
either from search results or by entering their own list; com-
bine lists using the Boolean operators ‘AND’, ‘OR’ and
‘NOT IN’; find common items between two lists. Lists can
be saved and used for further operations, for example ex-
port. Entries can be exported in their entirety, or the user
can customize which content they wish to export, for in-
stance the sequence or a subset of annotation types like
PTMs or expression profiles.
A major advance in the neXtProt functionality is the
availability of a new advanced search system, designed to
support the retrieval of proteins based on highly precise
criteria taking into account the richness of the annota-
tions and evidences. To implement this new functionality,
we have converted the relational database into a graph rep-
resentation using a subject-predicate-object model, RDF-
based (Resource Description Framework). The graph rep-
resentation is extremely powerful to navigate through the
richness of the neXtProt data and to search it using the
SPARQLquery language. The advanced search is accessible
at http://search.nextprot.org. An example query is shown in
Figure 4.
The syntax of the SPARQL query language is admittedly
complex. We have made efforts to remedy to this by choos-
ing predicate names that are as intuitive and distinctive as
possible.We also plan to add pre-calculated ‘shortcut’ pred-
icates. For instance, predicates expressing positional rela-
tionships between features (such as: next to, overlaps with,
upstream, downstream, etc.) would improve readability, ex-
pressivity and performance of queries.
Moreover, to assist users construct queries, we provide
a help page describing the data model where the domain
and range of each predicate is given as well and a list of key
resources (quality qualifiers, data sources, protein existence
levels, etc.). We also provide a wealth of examples of queries
that can be used directly or modified by users. Users can
also save their queries; and keep those either private ormake
them available publicly. Examples of queries are shown in
Figure 5.
The advanced search will also be available via a
SPARQL endpoint (http://api.nextprot.org/sparql). Using
a SPARQL-based technology also allows performing fed-
erated queries with external resources that also offer a
SPARQL endpoint. We provide examples of federated
queries with DrugBank (http://www.drugbank.ca (27)) and
with UniProtKB.
FOCUS ON QUALITY
neXtProt aims to be both comprehensive and of high qual-
ity. Hence, although we aim to integrate as much relevant
data as possible, the datasets are carefully selected and
the quality of the data determined upon loading in the
database; data deemed of low quality is excluded by data
filtering. For each dataset and controlled vocabulary inte-
grated in neXtProt, spot checks covering all types of the
data are performed in order to ensure that the data is prop-
erly parsed, displayed in our web site and present in the ex-
Figure 3. The neXtProt list manager can be used to save lists, make operations such as combining them, and export the entries contained in a list. The full
entries can be exported, or only certain data, such as accession numbers, the overview, the general annotations, etc.
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Figure 4. Example of a neXtProt advanced search. This query retrieves entries corresponding to proteins having a PDZ domain and that interact with at
least one protein expressed in the brain. The query returns 129 entries. Results can be sorted according to gene name, protein name, protein family name,
chromosome, accession number or protein length. The results can also be saved as list, and that list exported in different formats such as text, XML or
JSON.
Figure 5. Examples of SPARQL queries available in the advanced search page. The examples cover a wide range of different queries and many incorporate
counts of objects (for example, retrieve proteins having three disulfide bonds).
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port files. Problems identified in a dataset are immediately
communicated to the data source contributing to a virtuous
circle and resulting in improved data quality. Many checks
are also performed at each neXtProt release to ensure data
integrity and retrievability, tool functionality as well as the
proper implementation of new features.
DATA AVAILABILITY
Like any other neXtProt annotation, the variant data is
available in our export files in XML and PEFF formats (de-
scribed in (1)) on our FTP site (ftp://ftp.nextprot.org/). They
can also be accessed from our API at http://api.nextprot.
org. This content is available under the Creative Commons
Attribution-NoDerivs License.
CONCLUSIONS
neXtProt is being built as a participative platform and we
look forward to receiving users’ input for the future devel-
opment of neXtProt. Next developments include the con-
tinued expansion of the types of data captured in neXtProt.
We also wish to support users who will take advantage of
our API to incorporate some of neXtProt data into new
bioinformatics applications. This will allow these applica-
tions to benefit from our efforts in providing high-quality
curated knowledge on human proteins.
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